Answers are grounded in this paper and cite their sources.
Thrombotic complications characterize the clinical course of polycythemia vera (PV) and represent the main cause of morbidity and mortality. However, uncertainty still exists as to the benefit/risk ratio of aspirin prophylaxis in this setting. In vivo platelet biosynthesis of thromboxane A2 is enhanced and can be suppressed by low-dose aspirin in PV, thus providing a rationale for assessing the efficacy and safety of a low-dose aspirin regimen in these patients.
No takes yet. Share an insight, caveat, or question.
Landolfi et al. (1997) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: